This website contains promotional content and is intended for Healthcare Professionals based in the United States only.

Campus

Welcome to Sanofi Campus US

Article
Campus Sanofi
Jun 11, 2024

A hub for healthcare professionals to discover and find information on our medicines and therapies

Scientific News

View all

A Healthcare professional in a discussion with a patient

ArticleSep 9, 2024

Exploring Factor VIII Replacement Therapies: A Guide to Choosing the Right Treatment for Patients With Hemophilia A

Ensuring optimal care for patients with hemophilia A requires a thorough understanding of available treatment options, prioritization of bleed prevention and long-term joint health, and comprehensive patient education. This article will cover different types of factor VIII replacement therapies^* and will compare an on-demand versus prophylactic treatment approach with the goal of helping tailor treatment plans effectively, which can help enhance quality of life.

Learn more

ArticleJun 11, 2024

Welcome to Sanofi Campus US

A hub for healthcare professionals to discover and find information on our medicines and therapies

Learn more

ArticleFeb 28, 2024

Hemophilia B is different. Let’s manage it that way

It's time to look at the bigger picture in hemophilia B

Learn more

View all

MAT-US-2405606-v1.0-06/2024

Sitemap Legal Notice Privacy Policy Cookie Policy Do Not Sell or Share My Personal Information Contact

Therapeutic Areas
- Rare Blood Disorders
  - Hemophilia B
  - Hemophilia A
- Other topics
  - General Topics
- Diabetes
  - Type 2 Diabetes
Articles
- Other topics
  - General Topics
- Rare Blood Disorders
  - Hemophilia A
  - Hemophilia B
- Diabetes
  - Type 2 Diabetes
Resources
- Rare Blood Disorders
  - Hemophilia B
Products
- Thyrogen® (thyrotropin alfa) for injection
- Avalide® (irbesartan-hydrochlorothiazide)
- Cerdelga® (eliglustat) capsules
- Sarclisa® (isatuximab-irfc) injection for intravenous use
- Lantus® dosage and administration
- Ambien® (zolpidem tartrate) tablets
- Lantus® (insulin glargine injection) 100 Units/mL
- LEMTRADA® (alemtuzumab)
- Kevzara® (sarilumab) injection
- Rifadin® IV (rifampin for injection, USP)
- Ferrlecit® (sodium ferric gluconate complex in sucrose injection)
- Plavix® (clopidogrel bisulfate)
- Zaltrap® (ziv-aflibercept) Injection for intravenous infusion
- Apidra® (insulin glulisine injection) 100 Units/mL
- Xenpozyme® (olipudase alfa-rpcp) for injection, 20mg
- ALTUVIIIO® [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl]
- Ambien CR® (zolpidem tartrate) extended-release tablets
- Cerezyme® (imiglucerase) for injection
- Lumizyme® (alglucosidase alfa)
- Renvela® (sevelamer carbonate)
- Tzield® (teplizumab-mzwv) injection 2mg/2mL
- Dupixent® (dupilumab) injection
- Flomax® (tamsulosin HCI) capsules
- Cablivi® (caplacizumab-yhdp)
- Caprelsa® (vandetanib) Tablets
- Jevtana® (cabazitaxel) injection
- Elitek® (rasburicase) IV infusion
- Clolar® (clofarabine injection)
- Mozobil® (plerixafor) injection
- ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein]
- Aldurazyme® (laronidase)
- Synvisc-One® (hylan G-F 20)
- Toujeo® (insulin glargine injection) 300 Units/mL
- Amaryl® (glimepiride tablets)
- Hectorol® (doxercalciferol) injection
- Avapro® (irbesartan)
- Arava® Tablets (leflunomide)
- Aubagio® (teriflunomide)
- Priftin® (rifapentine) Tablets
- Synvisc® (hylan G-F 20)
- Fabrazyme® (agalsidase beta)
- Nexviazyme™ (avalglucosidase alfa-ngpt)
- multaq (dronedarone)
- Thymoglobulin® [Anti-thymocyte Globulin (Rabbit)]
- Rezurock (belumosudil) tablets
- Renagel® Tablets (sevelamer hydrochloride) 800mg tablets
- Beyfortus® (nirsevimab-alip) injection
- ADMELOG® (insulin lispro injection) 100 Units/mL
- Lovenox® (enoxaparin sodium injection) - 2
- ENJAYMO® (sutimlimab-jome) injection for intravenous use
- Primaquine® (Primaquine Phosphate Tablets)
- Alprolix® [Coagulation Factor IX (Recombinant), Fc Fusion Protein]
- Soliqua® 100/33 (insulin glargine and lixisenatide) injection 100 Units/mL and 33 mcg/mL